 DEER PARK, Ill., May 28, 2021 GLOBE NEWSWIRE -- Eton Pharmaceuticals, Inc Nasdaq: ETON, today announced that the company has received a Complete Response Letter CRL from the U.S. Food Drug Administration FDA in response to the submission of its New Drug Application NDA for dehydrated alcohol injection for the treatment of methanol poisoning. The CRL indicated that the FDA has completed its review of the application and has determined that the application cannot be approved in its present form. A Pre-Approval Inspection PAI of the products European contract manufacturer is pending due to what the company believes are COVID-related travel restrictions. The company believes all other FDA questions raised in the letter can be fully addressed in a response in the coming months. 